secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001493152-26-007190
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q3 FY2026 revenue up 120% to $31.6M; net income $18.6M
-------------------------------------------------------------------

- Revenue $31.6M, +120% YoY; income from operations $9.0M, +721% YoY.
- Net income $18.6M for three months ended Dec 31, 2025.
- Growth driven by lisdexamfetamine and naltrexone product launches after prior year comparable period.
- Conference call Feb 18, 2026 at 11:30 AM EST; questions due by Feb 17 evening.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/0001493152-26-007190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer